Lipitor, also known as atorvastatin, is a medication used to lower cholesterol levels in the blood and reduce the risk of heart disease and stroke [1]. According to a study published in the Journal of Diabetes and Metabolic Disorders, atorvastatin treatment has been associated with an increased risk of developing type 2 diabetes mellitus and metabolic syndrome [2]. However, a press release by Pfizer, the manufacturer of Lipitor, claims that the medication provides "unprecedented cardiovascular risk reductions" in patients with metabolic syndrome and stroke [3].

The study published in the Journal of Diabetes and Metabolic Disorders suggests that the use of atorvastatin may lead to an increased risk of developing metabolic syndrome and type 2 diabetes mellitus. The study found that patients taking atorvastatin had a higher incidence of developing diabetes compared to those not taking the medication. The study also found that atorvastatin use was associated with an increased risk of developing metabolic syndrome [2].

On the other hand, Pfizer claims that Lipitor provides "unprecedented cardiovascular risk reductions" in patients with metabolic syndrome and stroke. According to their press release, Lipitor reduced the risk of cardiovascular events by 43% in patients with metabolic syndrome and by 48% in stroke patients [3]. However, it is important to note that this press release is not a peer-reviewed study and may be biased towards promoting the medication.

In conclusion, while Lipitor has been shown to effectively lower cholesterol levels and reduce the risk of heart disease and stroke, there is evidence to suggest that its use may contribute to the development of metabolic disorders such as type 2 diabetes mellitus and metabolic syndrome. It is important for patients to discuss the risks and benefits of Lipitor with their healthcare provider before starting treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LIPITOR
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183966/
[3] https://www.pfizer.com/news/press-release/press-release-detail/lipitor_provides_unprecedented_cardiovascular_risk_reductions_in_diabetes_patients_with_metabolic_syndrome_and_in_stroke_patients.